



INNERSCOPE HEARING TECHNOLOGIES, INC.

A Nevada Corporation

2151 Professional Drive 2nd Floor,
Roseville, CA., 95661

833-788-0506

www.innd.com

info@innd.com

SIC Code: 5999

**Quarterly Report
For the Period Ending:**

06/30/2022

(the "Reporting Period")

As of June 30, 2022, the number of shares outstanding of our Common Stock was:

7,323,973,266

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

7,134,403,711

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

6,660,204,051

Indicate by check mark whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the Company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the Company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

InnerScope Hearing Technologies, Inc

InnerScope Advertising Agency, Inc. until August 2017

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, current

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

The address(es) of the issuer's principal executive office:
2151 Professional Drive, Second Floor, Roseville, CA 95661

The address(es) of the issuer's principal place of business:
Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol: INND
Exact title and class of securities outstanding: Common Stock
CUSIP: 45781P104
Par or stated value: \$0.0001

Total shares authorized: 14,975,000,000 as of date: August 10, 2022
Total shares outstanding: 7,407,342,166 as of date: August 10, 2022
Number of shares in the Public Float²: 6,331,741,121 as of date: August 10, 2022
Total number of shareholders of record: 77 as of date: August 10, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: N/A
Exact title and class of securities outstanding: N/A
CUSIP: N/A
Par or stated value: N/A
Total shares authorized: N/A as of date: _____
Total shares outstanding: N/A as of date: _____

Transfer Agent

Name: VStock Transfer Company
Phone: 212-828-8436
Email: yoel@vstocktransfer.com
Address: 18 Lafayette Place, Woodmere, NY 11598

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Is the Transfer Agent registered under the Exchange Act? ³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer’s securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares Outstanding as of Second Most Recent Fiscal Year End:		*Right-click the rows below and select "Insert" to add rows as needed.							
Opening Balance									
Date <u>12/31/19</u>									
Common: <u>342,118,136</u>									
Preferred: 900,000									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
1/2/2020	Issuance	14,823,683	Common	9,339	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
1/8/2020	Issuance	16,961,952	Common	10,686	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/9/2020	Issuance	17,696,079	Common	11,149	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/10/2020	Issuance	17,371,683	Common	10,944	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
1/16/2020	Issuance	20,387,179	Common	11,417	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

1/21/2020	Issuance	21,301,476	Common	8,947	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/23/2020	Issuance	15,997,204	Common	7,839	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
1/24/2020	Issuance	22,465,245	Common	11,008	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/27/2020	Issuance	23,498,714	Common	9,869	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/27/2020	Issuance	19,030,000	Common	9,325	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/28/2020	Issuance	23,503,500	Common	9,871	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/29/2020	Issuance	23,492,082	Common	11,511	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
1/30/2020	Issuance	23,546,490	Common	11,511	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/30/2020	Issuance	28,752,452	Common	12,076	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/4/2020	Issuance	23,922,694	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/7/2020	Issuance	32,328,048	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/10/2020	Issuance	20,981,914	Common	7,344	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
2/10/2020	Issuance	34,119,371	Common	11,942	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/11/2020	Issuance	25,111,371	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/13/2020	Issuance	28,509,036	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/18/2020	Issuance	39,031,524	Common	8,197	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
2/19/2020	Issuance	41,373,000	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/20/2020	Issuance	43,553,333	Common	9,146	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
2/20/2020	Issuance	45,243,190	Common	9,501	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/20/2020	Issuance	41,572,619	Common	8,900	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/24/2020	Issuance	44,127,333	Common	9,117	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/25/2020	Issuance	50,113,524	Common	10,524	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
2/25/2020	Issuance	35,069,476	Common	7,365	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
3/2/2020	Issuance	55,193,714	Common	11,591	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
3/4/2020	Issuance	48,951,286	Common	6,853	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
3/9/2020	Issuance	61,739,142	Common	8,493	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
3/11/2020	Issuance	63,971,143	Common	8,956	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
3/16/2020	Issuance	67,935,000	Common	4,755	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
3/18/2020	Issuance	67,953,857	Common	4,607	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
3/19/2020	Issuance	70,725,429	Common	4,951	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
3/23/2020	Issuance	77,104,857	Common	5,397	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
3/25/2020	Issuance	82,003,142	Common	5,590	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
3/25/2020	Issuance	79,969,571	Common	5,598	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144

OTC Markets Group Inc.

3/31/2020	Issuance	89,347,429	Common	6,254	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
3/31/2020	Issuance	83,035,429	Common	5,812	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
4/1/2020	Issuance	90,250,857	Common	6,168	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
4/3/2020	Issuance	102,753,499	Common	7,049	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
4/6/2020	Issuance	100,072,000	Common	7,005	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
4/6/2020	Issuance	103,000,000	Common	5,150	Yes	Crown Bridge Partners, LLC	Conversion	Unrestricted	Rule 144
4/13/2020	Issuance	118,501,285	Common	8,295	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
4/15/2020	Issuance	118,000,000	Common	5,900	Yes	Crown Bridge Partners, LLC	Conversion	Unrestricted	Rule 144
4/21/2020	Issuance	130,000,000	Common	6,500	Yes	Crown Bridge Partners, LLC	Conversion	Unrestricted	Rule 144
4/21/2020	Issuance	127,758,857	Common	8,943	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
4/28/2020	Issuance	129,466,143	Common	9,063	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
4/28/2020	Issuance	88,016,000	Common	6,161	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
5/1/2020	Issuance	154,000,000	Common	7,700	Yes	Crown Bridge Partners, LLC	Conversion	Unrestricted	Rule 144
5/5/2020	Issuance	154,266,667	Common	42,000	Yes	Adar Alef LLC	Conversion	Unrestricted	Rule 144
5/7/2020	Issuance	56,106,000	Common	3,927	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
10/26/2020	Issuance	94,581,142	Common	6,621	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
10/30/2020	Issuance	77,717,285	Common	5,440	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/20/2021	Issuance	180,606,286	Common	12,642	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/25/2021	Issuance	104,373,079	Common	7,306	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/26/2021	Issuance	144,915,571	Common	20,288	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
1/27/2021	Issuance	202,271,857	Common	28,318	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
1/29/2021	Issuance	105,432,138	Common	14,761	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/2/2021	Issuance	200,303,457	Common	70,106	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
2/2/2021	Issuance	120,822,135	Common	16,915	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/4/2021	Issuance	133,997,771	Common	46,899	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/4/2021	Issuance	29,750,190	Common	6,248	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/5/2021	Issuance	35,122,032	Common	19,668	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/6/2021	Issuance	216,000,000	Common	14,500	Yes	Crown Bridge P	Conversion	Unrestricted	Rule 144
2/9/2021	Issuance	243,100,000	Common	14,586	Yes	Adar Alef LLC	Conversion	Unrestricted	Rule 144
2/10/2021	Issuance	113,352,386	Common	79,347	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/18/2021	Issuance	68,342,596	Common	191,359	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
2/18/2021	Issuance	64,362,967	Common	157,689	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
2/23/2021	Issuance	20,395,770	Common	68,530	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
3/1/2021	Issuance	11,804,739	Common	12,395	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144

3/1/2021	Issuance	18,383,489	Common	51,477	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
3/3/2021	Issuance	30,422,113	Common	330,080	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
3/22/2021	Issuance	11,797,494	Common	117,804	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
4/07/2021	Issuance	11,609,746	Common	130,029	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
4/12/2021	Issuance	24,508,770	Common	274,498	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
4/12/2021	Issuance	5,897,424	Common	71,418	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
4/12/2021	Issuance	5,615,918	Common	68,009	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
4/12/2021	Issuance	26,848,584	Common	325,136	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
5/19/2021	Issuance	24,540,793	Common	262,832	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
5/20/2021	Issuance	25,986,810	Common	274,681	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
6/14/2021	Issuance	18,306,697	Common	187,094	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
6/17/2021	Issuance	16,390,102	Common	157,181	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
7/19/2021	Issuance	10,662,085	Common	91,694	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
7/19/2021	Issuance	22,654,036	Common	160,844	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
7/22/2021	Issuance	10,672,267	Common	91,781	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
7/29/2021	Issuance	13,266,511	Common	114,092	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
8/5/2021	Issuance	2,000,000	Common	2,600	Yes	Patrick Muchiri	Employee Stock	Restricted	Rule 144
8/5/2021	Issuance	41,000,000	Common	565,800	Yes	New to the Street Group LLC	Consultant	Restricted	Rule 144
8/5/2021	Issuance	4,000,000	Common	4000	Yes	David Valerio	Employee Stock	Restricted	Rule 144
8/5/2021	Issuance	2,124,378	Common	11,897	Yes	Frederick Abromeit	Employee Stock	Restricted	Rule 144
8/5/2021	Issuance	3,000,000	Common	86,400	Yes	Ajo Capital Inc.	Consultant	Restricted	Rule 144
8/20/2021	Issuance	22,416,520	Common	118,808	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
8/20/2021	Issuance	19,180,912	Common	111,249	Yes	Odyssey Capital Funding LLC	Conversion	Unrestricted	Rule 144
9/14/2021	Issuance	25,212,470	Common	148,754	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
12/15/2021	Issuance	19,121,953	Common	267,584	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
11/18/2021	Issuance	30,000,000	Common	300,000	Yes	GS Capital Partners, LLC	Cash	Restricted	Rule 144
12/27/2021	Issuance	99,141,854	Common	882,363	Yes	Nicholas Naylor	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	330,467,697	Common	2,941,163	Yes	Floyd Kuriloff	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	33,046,770	Common	294,116	Yes	Anthony Bender	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	99,141,854	Common	882,363	Yes	Tana Manning	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	5,190,368	Common	46,194	Yes	Nicholas Naylor	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	17,300,956	Common	153,979	Yes	Floyd Kuriloff	Acquisition	Restricted	Rule 144
12/27/2021	Issuance	1,730,096	Common	15,398	Yes	Anthony Bender	Acquisition	Restricted	Rule 144

12/27/2021	Issuance	5,190,368	Common	46,194	Yes	Tana Manning	Acquisition	Restricted	Rule 144
09/30/2021	Issuance	400,000	Preferred Series C	666,667	Yes	iHear Medical, Inc	Asset Purchase	Restricted	Rule 144
01/13/2022	Issuance	10,000,000	Common	100,000	Yes	GS Capital Partners, LLC	Cash	Restricted	Rule 144
01/20/2022	Issuance	25,000,000	Common	250,000	Yes	GS Capital Partners, LLC	Cash	Restricted	Rule 144
02/01/2022	Issuance	279,085,400	Common	27,909	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
02/24/2022	Issuance	12,650,602	Common	64,518	Yes	Benjamin Francis	Consultant	Restricted	Rule 144
02/24/2022	Issuance	55,000,000	Common	280,500	Yes	Josh Howard	Consultant	Restricted	Rule 144
02/24/2022	Issuance	60,003,203	Common	300,016	Yes	North Equity Corp	Consultant	Restricted	Rule 144
03/24/2022	Issuance	32,460,455	Common	104,523	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
04/04/2022	Issuance	25,323,886	Common	88,634	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
04/06/2022	Issuance	13,169,269	Common	46,092	Yes	Eagle Equities, LLC	Conversion	Unrestricted	Rule 144
05/12/2022	Issuance	110,570,800	Common	11,057	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144
06/21/2022	Issuance	40,505,600	Common	4,051	Yes	GS Capital Partners, LLC	Conversion	Unrestricted	Rule 144

Shares Outstanding on Date of This Report:	
<u>Ending</u> <u>Balance</u>	
<u>Ending Balance:</u>	
Date 06/30/2022 Common: 7,323,973,266	
Preferred Series B: 900,000	
Preferred Series C: 400,000	

Example: A company with a fiscal year end of December 31, in addressing this item for its year ended December 31, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through December 31, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

GS Capital- Gabe Sayegh has voting control Eagle Equities- Yanky Borenstein has voting control New to the Street Group LLC- Vince Caruso has voting control Ajo Capital Inc. - Dror Tepper has voting control	Odyssey Capital Funding LLC-Ahron Fraiman has voting control Crown Bridge- Seth Ahdoon has voting control Adar Alef-Ari Goldstein has voting control iHEAR Medical – Adnan Shennib
--	---

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
11/1/2019	32,158	32,158	15,271	11/1/2020	discount of 30% to the lowest trading price for the 15 days prior to conversion	Adar Alef	Convertible Note Payable
1/30/2020	23,200	23,200	14,586	2/1/2021	discount of 30% to the lowest trading price for the 15 days prior to conversion	GS Capital	Convertible Note Payable

2/4/2021	195,000	195,000	36,884	2/5/2022	<u>discount of 30% to the lowest trading price for the 15 days prior to conversion</u>	GS Capital	Convertible Note Payable
09/30/2021	1,000,000	1,000,000	37,397	09/30/2023	<u>discount of 10% to the lowest trading price for the 5 days prior to conversion</u>	iHear Medical, Inc.	Purchase of assets
02/18/2022	262,000	262,000	23,429	11/18/2022	<u>Converts at \$0.01 per share</u>	GS Capital	Convertible Note Payable
03/11/2022	262,000	262,000	23,429	12/11/2022	<u>Converts at \$0.01 per share</u>	GS Capital	Convertible Note Payable
03/30/2022	262,000	262,000	23,429	12/31/2022	<u>Converts at \$0.01 per share</u>	GS Capital	Convertible Note Payable
04/13/2022	262,000	262,000	7,838	01/23/2023	<u>Converts at \$0.01 per share</u>	GS Capital	Convertible Note Payable
05/24/2022	330,000	330,000	9,873	02/24/2023	<u>Converts at \$0.01 per share</u>	GS Capital	Convertible Note Payable
06/08/2022	162,500	162,500	4,862	06/08/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
06/13/2022	265,625	265,625	7,947	06/13/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
06/21/2022	91,750	91,750	2,745	06/21/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
06/23/2022	113,335	113,335	3,391	06/23/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
04/29/2022	250,000	250,000	7,838	04/29/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
05/24/2022	600,000	600,000	10,471	05/24/2023	<u>Non-Convertible</u>	GS Capital	Note Payable
05/24/2022	300,000	300,000	5,236	05/24/2023	<u>Non-Convertible</u>	GS Capital	Note Payable

Use the space below to provide any additional details, including footnotes to the table above:

GS Capital- Gabe Sayegh has voting control
Adar Alef-Ari Goldstein has voting control
iHEAR Medical – Adnan Shennib

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual):

Name: Kim Moore
Title: CFO
Relationship to Issuer: CFO

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
D. Statement of income;
E. Statement of cash flows;

OTC Markets Group Inc.

- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

InnerScope Hearing Technologies, Inc. ("Company," "InnerScope") is a Nevada Corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The Company was originally named InnerScope Advertising Agency, Inc. and was formed to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc. to better reflect the Company's current direction as a hearing health technology company that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) with a scalable business model.

- B. Please list any subsidiaries, parents, or affiliated companies.

Hearing Assist Direct Inc.,
Hearing Assist II Inc.
iHEAR

- C. Describe the issuers' principal products or services.

The Company is a manufacturer and a distributor/retailer of Direct-to-Consumer ("DTC") FDA (Food and Drug Administration) registered hearing aids, personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements ("Hearing Products"). The Company's mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues. The management team of InnerScope is applying decades of industry experience and believes it is well-positioned with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks ("Hearing Kiosks") to directly benefit when the Over-the-Counter (OTC) Hearing Aid Act (the "OTC Hearing Aid Law") becomes enacted (expected 4th quarter 2022) (the OTC Hearing Aid Law allows OTC hearing aids for mild to moderate hearing losses to be sold in retail stores without having to see a professional).

The Hearing Kiosk is designed for the tens of millions of Americans with undetected/untreated mild-to-moderate hearing losses to treat themselves with the Company's easy, convenient, and affordable OTC hearing aids in-store off-the-shelf and/or DTC online affordable hearing aid options.

The company's full line of Hearing Health products is currently available through these multiple retail/wholesale channels: Walmart Brick & Mortar Locations, Walmart.com, Walmart Canada, RiteAid.com, BestBuy.com, Amazon.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, FingerHut.com, and Cardinal Health dba RGH Enterprises Inc., which

OTC Markets Group Inc.

provides InnerScope products to FSASore.com, HSASore.com, & WellDeservedHealth.com. Additional in-store and online through major retailers and pharmacy chains are launching soon.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

InnerScope Hearing Technologies Locations as of 06/30/2022

<u>Location Name</u>	<u>Purpose</u>	<u>Address</u>	<u>Rent</u> (per Month)	<u>Start Date</u>	<u>End Date</u>	<u>Condition</u>
InnerScope HQ	Corporate	2151 Professional Drive 2nd Floor, Roseville, CA., 95661	\$12,000	5/1/2022	4/30/2022	In good condition & sufficient for the Company's current needs
Hearing Assist HQ	Corporate	3502 Pacific Ave Virginia Beach, VA 23451	\$3,500	02/01/2021	04/30/2024	In good condition & sufficient for the Company's current needs
iHEAR HQ	Corporate	15250 Hesperian Blvd, Suite 102 San Leandro, CA 94578	\$5,800	10/01/2021	03/31/2022	In good condition & sufficient for the Company's current needs

Investment in Undivided Interest in Real Estate

InnerScope Hearing Technologies has 49% ownership of a Commercial property located at 2151 Professional Drive, Roseville, CA., 95661. A related party owns the remaining 51%.

Business Acquisition

InnerScope Hearing Technologies purchased 100% of Hearing Assist II, INC., on November 22, 2021. Hearing Assist II, INC., is consolidated within the financial statement.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the Company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Matthew Moore</u>	<u>CEO</u>	<u>Roseville, CA</u>	<u>19,020,000</u>	<u>Common</u>	<u>0.003%</u>	_____
<u>Matthew Moore</u>	<u>CEO</u>	<u>Roseville, CA</u>	<u>300,000</u>	<u>Series B</u>	<u>33.33%</u>	_____
<u>Kim Moore</u>	<u>CFO</u>	<u>Granite Bay, CA</u>	<u>19,020,000</u>	<u>Common</u>	<u>0.003%</u>	_____
<u>Kim Moore</u>	<u>CFO</u>	<u>Granite Bay, CA</u>	<u>300,000</u>	<u>Series B</u>	<u>33.33%</u>	_____
<u>Mark Moore</u>	BOARDMEMBER	<u>Granite Bay, CA</u>	<u>19,020,000</u>	<u>Common</u>	<u>0.003%</u>	_____
<u>Mark Moore</u>	BOARDMEMBER	<u>Granite Bay, CA</u>	<u>300,000</u>	<u>Series B</u>	<u>33.33%</u>	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

Yes

Mark L. Moore, as an Affiliate and a California Licensed Hearing Aid Dispenser, was party to an Investigation conducted by the California Speech-Language Pathology & Audiology & Hearing Aid Dispensing Board for provisions of the California Civil Code Section 1790 (the Song-Beverly Consumers Warranty Act.)

As a result of the mentioned investigation above, Mark L. Moore, and Kimberly A. Moore also an Affiliate and a California Licensed Hearing Aid Dispenser and Matthew R. Moore were imposed Civil Penalties pursuant to an executed Stipulated Final Judgment and agreed to not violate certain sections of the California Business and Professions code. In summary, Matthew Moore and Affiliates are not barred nor restricted in ownership or management of a hearing aid company in CA.

A Stipulation of Entry for Final Judgment described above, was entered into on March 7, 2017, which settled all claimed violations by Mark L. Moore, and Kimberly A. Moore, Affiliates, and Matthew R. Moore, & etal. without taking any evidence, and without the trial or adjudication of any issue of the law or fact, and any admission of the truth of any allegation and without any inference or presumption which may arise by reason of entering into the Stipulation of Entry of Final Judgment.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Investor Relations

Name: Lisa Gray, Senior Account Manager
Firm: Skyline Corporate Communications Group, LLC
Address 1: One Rockefeller Plaza
Address 2: 11th Floor
Phone: (646) 893-5835
Email: lisa@skylineccg.com

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

OTC Markets Group Inc.

I, Matthew Moore certify that:

1. I have reviewed this Quarterly Disclosure Statement of InnerScope Hearing Technologies Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 11, 2022

/s/ Matthew Moore [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Kim Moore certify that:

1. I have reviewed this Quarterly Disclosure Statement of InnerScope Hearing Technologies Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 11, 2022

/s/ Kim Moore [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS

	As of June 30	
	2022	2021
ASSETS		
Current Assets:		
Cash	\$ 110,577	\$ 76,115
Accounts receivable, allowance for doubtful accounts	6,688,293	640,900
Accounts receivable from related party	149,042	296,946
Employee advances	4,000	(4,400)
Prepaid assets	58,644	100,254
Inventory	2,237,624	343,441
Total current assets	9,248,180	1,453,256
Security deposits	-	6,750
Domain name	10,000	3,000
Other assets	6,518	-
Intangible assets, net of accumulated amortization	13,122,793	879,336
Property and equipment, net of accumulated depreciation	217,937	101,101
Operating leases right-of-use assets, net	-	327,261
Investment in undivided interest in real estate	1,252,206	1,216,973
Total assets	\$ 23,857,633	\$ 3,987,677
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities:		
Bank fees	\$ 25,037	\$ 509
Accounts payable and accrued expenses	7,644,469	690,091
Accounts payable to related party	-	721,087
Notes payable - stockholder	95,800	95,800
Current portion of convertible notes payable, net of discounts	920,160	1,398,456
Loan payable	3,227,590	-
Note payable, other & related party	68,082	1,147,520
Customer deposits	3,632	3,632
Income taxes payable	-	23,998
Derivative liabilities	993,642	2,247,460
Operating lease liabilities, current portion	301,812	396,138
Total current liabilities	\$ 13,280,224	6,724,691
Long term portion of note payable- undivided interest in real estate	960,152	905,008
EIDL loan	161,326	-
Long-term portion of convertible notes payable	1,000,000	-
Other long-term liability	5,097,346	-
Operating lease liabilities, Less current portion	43,596	-
Total liabilities	\$ 20,542,644	7,629,699
Commitments and contingencies		
Stockholders' Deficit:		
Preferred stock, \$0.0001 par value; 25,000,000 shares authorized;		
Series A preferred stock, par value \$0.0001, -0- (2022) and -0- (2021)	-	-
Series B preferred stock, par value \$0.0001, 900,000 (2022) and 900,000 (2021) shares authorized, and 900,000 (2022) and 900,000 (2021) shares issued and outstanding	90	90
Series C preferred stock, par value \$0.0001, 10,000,000 (2022) and -0- (2021) shares authorized, and 400,000 (2022) and 0 (2021) shares issued and outstanding	40	-
Common stock, \$0.0001 par value; 14,975,000,000 (2022) and 14,975,000,000 (2021) shares authorized and 7,323,973,266(2022) and 5,843,682,956 (2021) shares issued and outstanding	732,399	569,997
Common stock to be issued, \$0.0001 par value, 2,412,671 (2022) and 2,412,671 (2021) shares	241	241
Additional paid-in capital	71,440,431	9,929,152
Accumulated deficit	(68,858,212)	(14,141,502)
Total stockholders' deficit	3,314,989	(3,642,022)
Total Liabilities and Shareholder Equity	\$ 23,857,633	\$ 3,987,677

See notes to consolidated financial statements.

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended June 30,	
	2022	2021
Revenues:		
Revenues, other	\$ 6,910,386	\$ 39,485
Total revenues	6,910,386	39,485
Cost of sales		
Cost of sales, other	\$ 3,172,451	9,387
Total cost of sales	3,172,451	9,387
Gross profit	\$ 3,737,935	\$ 30,098
Operating Expenses:		
Compensation and benefits	711,568	194,307
Advertising and promotion	122,111	3,974
Professional fees	65,802	49,469
Rent, including related party	86,384	47,469
Investor relations	33,500	18,626
Depreciation and Amortization expense	55,512	-
Other general and administrative	(37,136)	20,272
Total operating expenses	\$ 1,037,741	\$ 334,117
Profit from operations	\$ 2,700,194	\$ (304,019)
Other Income (Expense):		
Other income		
Derivative income (loss)	806,714	977,853
Gain (loss) on equity investment	12,179	-
Amortization of debt discount	(293,885)	-
Gain/Loss on debt extinguishment	996,846	66,942
Gain on lease termination	-	16,018
Interest expense and finance charges	(340,428)	(369,332)
Total other income (expense), net	\$ 1,181,426	\$ 691,481
NET Profit (EBT)	\$ 3,881,620	\$ 387,462
Income tax provision	-	-
Net Income (Loss)	\$ 3,881,620	\$ 387,462
Basic and diluted income (loss) per share	0.001	0.000
Weighted average number of common shares outstanding		
Basic and diluted	6,923,148,540	5,843,682,956

See notes to consolidated financial statements.

INNERSCOPE HEARING TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended June 30,	
	2022	2021
Cash flows from operating activities:		
Net Income	\$ 3,881,620	\$ 387,462
Adjustments to reconcile net income (loss) to net cash used in operations:	-	-
Loss on fair value of derivatives	(1,590,761)	(60,825)
Amortization of debt discounts	293,885	(284,356)
Depreciation and amortization	58,502	(68,100)
Note penalties	56,659	-
(Gain) loss on investment in undivided interest in real estate	(12,179)	-
(Gain) loss on debt extinguishment	(1,104,849)	66,942
Gain on lease terminations	-	16,018
Other general and operating expenses	-	(5,191)
Changes in operating assets and liabilities:	-	-
Accounts receivable	(5,778,365)	(10,793)
Employee advances	-	-
Inventory	(1,000,646)	(38,316)
Prepaid assets	(41,988)	-
Related party receivable	501,675	-
Accounts payable and accrued expenses	(881,299)	(169,166)
Other liabilities	3,546,049	-
Customer deposits	-	-
Officer salaries payable	-	-
Operating lease liabilities	5,574	126,355
Net cash used in operating activities	(2,066,123)	(39,970)
Cash flows from investing activities:		
Payment of security deposit	-	1,450
Purchase of office and computer equipment	57,313	-
Net cash used in investing activities	57,313	1,450
Cash flows from financing activities:		
Proceeds from issuance of note payable	1,497,625	-
Bank fees	3,900	-
Proceeds from issuance of common stock	-	-
Payments/Proceeds from convertible notes payable	406,203	155,000
Payments/Proceeds from loans	-	-
Repayments of note payable	-	(41,056)
Payable to related party	(7,500)	-
Net cash provided by financing activities	1,900,228	113,944
Net increase (decrease) in cash and cash equivalents	(108,582)	75,424
Cash and cash equivalents, Beginning of period	\$ 219,159	\$ 691
Cash and cash equivalents, End of period	\$ 110,577	\$ 76,115
Supplemental disclosure of cash flow information:		
Cash paid for interest	-	-
Cash paid for income taxes	-	-
Schedule of non-cash Investing or Financing Activity:		
Reclassification of derivative liabilities upon principal repayments of convertible notes		591,047
Conversion of notes payable and accrued interest in common stock	93,175	1,425,742
Operating lease right-of-use assets and liabilities		(378,335)

See notes to consolidated financial statements.

**CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT
THREE MONTHS ENDED JUNE 30, 2022 and 2021**

	Series B Preferred stock		Series C Preferred stock		Common stock		Common stock to be issued		Additional Paid-in Capital	Retained deficit	Total Stockholders' Deficit
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount			
Balances March 31, 2021	900,000	\$ 90	-	\$ -	5,683,978,112	\$ 568,399	2,412,671	\$ 241	\$ 7,913,960	\$ (14,528,964)	\$ (6,046,274)
Common stock issued for convertible notes and accrued interest	-	-	-	-	159,704,844	1,598	-	-	1,424,146	-	1,425,744
Reclassification of derivative liabilities upon payment of convertible debt	-	-	-	-	-	-	-	-	591,046	-	591,046
Net Income for the period ended June 30, 2021	-	-	-	-	-	-	-	-	-	387,462	387,462
Balances June 30, 2021	<u>900,000</u>	<u>\$ 90</u>	<u>-</u>	<u>\$ -</u>	<u>5,843,682,956</u>	<u>\$ 569,997</u>	<u>2,412,671</u>	<u>\$ 241</u>	<u>\$ 9,929,152</u>	<u>\$ (14,141,502)</u>	<u>\$ (3,642,022)</u>
Balances March 31, 2022	<u>900,000</u>	<u>\$ 90</u>	<u>400,000</u>	<u>\$ 40</u>	<u>7,134,403,711</u>	<u>\$ 713,442</u>	<u>2,412,671</u>	<u>\$ 241</u>	<u>\$ 71,309,554</u>	<u>\$ (72,739,832)</u>	<u>\$ (716,465)</u>
Common stock issued for convertible notes and accrued interest	-	-	-	-	189,569,555	18,957	-	-	130,877	-	149,834
Net Income for the period ended June 30, 2022	-	-	-	-	-	-	-	-	-	3,881,620	3,881,620
Balances June 30, 2022	<u>900,000</u>	<u>\$ 90</u>	<u>400,000</u>	<u>\$ 40</u>	<u>7,323,973,266</u>	<u>\$ 732,399</u>	<u>2,412,671</u>	<u>\$ 241</u>	<u>\$ 71,440,431</u>	<u>\$ (68,858,212)</u>	<u>\$ 3,665,323</u>

See notes to consolidated financial statements.

INNERSCOPE HEARING TECHNOLOGIES, INC
Notes to the Financial Statement
June 30, 2022 (Unaudited)

THE COMPANY

InnerScope Hearing Technologies, Inc. ("Company," "InnerScope") is a Nevada Corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The Company was originally named InnerScope Advertising Agency, Inc. and was formed to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc. to better reflect the Company's current direction as a hearing health technology company that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) with a scalable business model.

The Company is a manufacturer and a distributor/retailer of Direct-to-Consumer ("DTC") FDA (Food and Drug Administration) registered hearing aids, personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements. The Company's mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues. The management team of InnerScope is applying decades of industry experience and believes it is well-positioned with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks ("Hearing Kiosks") to directly benefit when the Over-the-Counter (OTC) Hearing Aid Act (the "OTC Hearing Aid Law") becomes enacted (expected 4th quarter 2022) (the OTC Hearing Aid Law allows OTC hearing aids for mild to moderate hearing losses to be sold in retail stores without having to see a professional). The Hearing Kiosk is designed for the tens of millions of Americans with undetected/untreated mild-to-moderate hearing losses to treat themselves with the Company's easy, convenient, and affordable hearing products. The Company's Hearing Products and its business model break through the persistent barriers that prevent access to effective hearing solutions. The Company's recent acquisition of iHear Medical Inc., a DTC cloud-based hearing solution provider, gives the Company access to over 40 patents and an FDA-registered manufacturing and R&D facility. In addition, the Company has acquired HearingAssist, an established leader in the direct-to-consumer hearing aid market with a customer base of over 400,000. These acquisitions, combined with a partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, will allow the Company to take the lead position in the direct-to-consumer hearing solutions market by selling innovated proprietary advanced hearing products through Walmart and other major Big Box retailers. The Company's full line of Hearing Health products is currently available through multiple retail/wholesale channels: Walmart Brick & Mortar Locations, Walmart.com, RiteAid.com, Amazon.com, BestBuy.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, FingerHut.com, and Cardinal Health dba RGH Enterprises Inc., which provides products to FSASStore.com, HSASStore.com, and WellDeservedHealth.com, with additional retailers and distribution points launching in the near future.

SIGNIFICANT ACCOUNTING POLICIES

The Company's accounting policies conform to the United States' generally accepted accounting principles and have been consistently applied in the preparation of these financial statements. The financial statements included herein have not been audited by an independent registered public accounting firm but include all adjustments (including normal, recurring entries), which are, in the opinion of management, necessary for a fair presentation of the results for such periods.

GENERAL PRINCIPLES

a) Estimates

The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosure. Accordingly, actual results could differ from those estimates.

b) Revenue Recognition

The Company recognizes revenue when earned in accordance with SEC Staff Accounting Bulletin No 101. "Revenue Recognition in Financial Statements."

c) Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents.

CONVERTIBLE NOTES PAYABLE

On February 5, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$195,000. The Note matures on February 5, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 5, 2021, when the Company received proceeds of \$176,000 after disbursements for the lender's transaction costs, fees, and expenses.

On February 25, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$165,000. The Note matures on February 25, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 25, 2021, when the Company received proceeds of \$155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On April 6, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$165,000. The Note matures on April 6, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 6, 2021, when the Company received proceeds of \$155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On July 7, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$165,000. The Note matures on July 6, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on July 7, 2021, when the Company received proceeds of \$155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On August 25, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$165,000. The Note matures on August 25, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to

conversion. The Note was funded on August 25, 2021, when the Company received proceeds of \$155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On September 20, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$165,000. The Note matures on September 20, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 13, 2021, when the Company received proceeds of \$155,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On September 30, 2021, the Company issued a convertible redeemable note (the "Note") with a face value of \$1,000,000 as part of consideration for purchased assets (see discussed below). The Note matures on September 30, 2023, has a stated interest of 5%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 90% of the lowest closing bid price for the 5 days prior to conversion.

On October 13, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$330,000. The Note matures on October 13, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 13, 2021, when the Company received proceeds of \$310,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On November 9, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$266,000. The Note matures on November 9, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 9, 2021, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On November 15, 2021, the Company sold 30 million shares for aggregate proceeds of \$300,000, of which a portion of the proceeds was utilized to pay principal and interest on an outstanding convertible loan in the aggregate amount of approximately \$70,000.

On December 21, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$266,000. The Note matures on December 21, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on December 21, 2021, when the Company received proceeds of \$200,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On January 13, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$158,000. The Note matures on January 13, 2023, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 13, 2021, when the Company received proceeds of \$150,000

after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On January 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$262,000. The Note matures October 28, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on January 28, 2022, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On February 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$262,000. The Note matures November 18, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on February 28, 2022, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 11, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$262,000. The Note matures December 11, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on March 11, 2022, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 30, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$262,000. The Note matures December 31, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on March 30, 2022, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On April 13, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$262,000. The Note matures January 23, 2023 has a stated interest of 6%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on April 13, 2022, when the Company received proceeds of \$250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On May 24, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of \$330,000. The Note matures February 24, 2023, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of \$0.01 per shares. The Note was funded on May 24 2022, when the Company received proceeds of \$300,000 after disbursements for the lender's transaction costs, fees, and expenses.

CONVENTIONAL NOTES PAYABLE

On April 29, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$262,000. The Note matures April 29, 2023, has a stated interest of 8% The Note was funded on April 29, 2022, when the Company received proceeds of \$262,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 8, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$162,500. The Note matures June 8, 2023, has a stated interest of 8%. The Note was

funded on June 8, 2022, when the Company received proceeds of \$150,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 13, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$265,625. The Note matures June 13, 2023, has a stated interest of 8% The Note was funded on June 13, 2022, when the Company received proceeds of \$255,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 21, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$91,750. The Note matures June 21, 2023, has a stated interest of 8% The Note was funded on June 21, 2022, when the Company received proceeds of \$85,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 23, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$113,335. The Note matures June 23, 2023, has a stated interest of 8% The Note was funded on June 23, 2022, when the Company received proceeds of \$105,000 after disbursements for the lender's transaction costs, fees, and expenses.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$600,000. The Note matures May 24, 2023, has a stated interest of 10%. The Note was funded on May 24, 2022, when the Company received proceeds of \$600,000. The note is secured by all company's assets.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of \$600,000. The Note matures May 24, 2023, has a stated interest of 10%. During period end June 30, 2022, Company received funds in the amount of \$300,000. Second half of the note amount was received subsequently to period end. The note is secured by the real property.

INVESTMENT IN UNDIVIDED INTEREST IN REAL ESTATE

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building, and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was \$2,420,000, and the total amount paid at closing was \$2,501,783, including fees, insurance, interest, and real estate taxes. In addition, the Company paid for their building interest by delivering cash at closing of \$209,971 and being a co-borrower on a note in the amount of \$2,057,000, of which the Company has agreed with LLC1 to pay \$1,007,930.

BUSINESS ACQUISITION

ASC Topic 805, "Business Combinations," requires that all business combinations be accounted for using the acquisition method and that certain identifiable intangible assets acquired in a business combination be recognized as assets apart from goodwill. ASC Topic 350, "Intangibles-Goodwill and Other" ("ASC 350"), requires goodwill and other identifiable intangible assets with indefinite useful lives not to be amortized, such as trade names, but instead tested at least annually for impairment and be written down if impaired. ASC 350 requires that goodwill be allocated to its respective reporting unit and that identifiable intangible assets with finite lives be amortized over their useful lives.

On November 22, 2021, the Company purchased Hearing Assist II, LLC. The Company acquired 100% interest in the entity for a total consideration of 591,209,963 common shares valued at \$8,513,423 on

the day of purchase. As part of the acquisition, the Company assumed assets in the amount of \$15,713,000, consisting of trademarks, domains, customer lists, customer contracts, licenses, royalties, other contracts, and liabilities in the amount of \$7,199,678.

ASSET PURCHASE

On September 30, 2021, the Company entered into an Asset Purchase agreement with iHear Medical, Inc. pursuant to which the Company received a number of intangible assets, equipment, customer database and inventory for a total consideration of 400,000 preferred series C shares and \$1,000,000 convertible note. Preferred shares valued at \$666,667 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of \$1,666,667, consisting of inventory, equipment, customer lists, patents and other technology-based intangibles.

NOTE PAYABLE - UNDIVIDED INTEREST IN REAL ESTATE

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building, and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was \$2,420,000, and the total amount paid at closing was \$2,501,783, including fees, insurance, interest, and real estate taxes. The Company is a co-borrower on a \$2,057,000 Small Business Administration Note (the "SBA Note"). The SBA Note carries a 25-year term, with an initial interest rate of 6% per annum, adjustable to the Prime interest rate plus 2%, and is secured by a first position Deed of Trust and business assets located at the property. The Company initially recorded a liability of \$1,007,930 for its portion of the SBA Note, with the offset being to Investment in undivided interest in real estate on the balance sheet presented herein.

DERIVATIVE LIABILITY

The Company determined that the conversion features of the convertible notes represented embedded derivatives since the Notes are convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under EITF 00-19, and the embedded conversion feature is bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of these derivative instruments is recorded as liabilities on the consolidated balance sheet, with the corresponding amount recorded as a discount to each Note, with any excess of the fair value of the derivative component over the face amount of the Note recorded as an expense on the issue date. Such discounts are amortized from the date of issuance to the maturity dates of the Notes. The change in the fair value of the derivative liabilities is recorded in other income or expenses in the condensed consolidated statements of operations at the end of each period, with the offset to the derivative liabilities on the balance sheet.

GOING CONCERN

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net profit of \$3,881,620 for the period ended June 30, 2022. The Company has an Accumulated deficit of \$68,858,212 for the period ended June 30, 2022. This raises doubt about the Company's ability to continue as a going concern and to operate in the normal course of business. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.